智通财经APP获悉，维立志博-B(09887)高开近3%，截至发稿，涨2.44%，报63港元，成交额458.64万港元。
消息面上，9月14日，维立志博-B发布公告，在2026年世界肺癌大会(WCLC 2026)以口头报告形式发布自主研发的在研药物维利信®(奥帕替苏米单抗，PD-L1/4-1BB双抗)联合化疗一线治疗非小细胞肺癌(NSCLC)患者的II期临床研究更新资料。根据更新资料，展现出前所未有的高缓解率，在鳞状NSCLC PD-L1阴性(PD-L1肿瘤比例评分(TPS)<1%)和阳性(PD-L1 TPS≥1%)患者中观察到几乎完全一致的临床获益，而非鳞状NSCLC PD-L1 TPS≥1%患者可获得深度且持久的肿瘤缓解。
作为全球首款已进入上市许可审评阶段的PD-L1/4-1BB双特异性抗体，维利信®凭借差异化双重作用机制，实现更深度的疗效应答和更广泛的临床获益，并在第一代肿瘤免疫疗法已确立的长尾生存获益基础上进一步延续该优势。目前，维利信®正在开展14个实体瘤适应症的临床研究，作为泛肿瘤免疫疗学(IO)2.0基石疗法的证据日益充分。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.